Literature DB >> 14630094

Glucocorticoid agonistic and antagonistic effects of mifepristone and onapristone on thymocyte subset composition and CD26/dipeptidyl peptidase IV activity in infant male rats.

Jirí Kraml1, Jirina Kolínská, Jirí Sinkora, Marie Zákostelecká, Libuse Kadlecová, Dana Hirsová, Lenka Nosková.   

Abstract

Antiglucocorticoid activities of two antigestagens-antiglucocorticoids (AGs)-mifepristone and onapristone-were tested in hydrocortisone-treated suckling male rats. Hydrocortisone (HC) treatment in vivo resulted in (1) reduction of the relative thymus weight and absolute thymocyte counts; (2) relative decrease of the CD4(+)CD8(+) thymocyte proportion accompanied by an increase of single-positive and double negative thymocyte populations, the latter of which contained large CD3-negative cells expressing a high level of CD26 on their surface; (3) increase of specific dipeptidyl peptidase IV (DPP IV) activity in thymocyte homogenates. Both AGs suppressed the systems (1) and (2) to a comparable extent. When administered alone, mifepristone and onapristone at higher doses exhibited a slight thymolytic effect as revealed by the reduction of the relative thymus weight and thymocyte counts, accompanied by some reduction of the numbers of cycling thymocytes. These effects were limited to the early postnatal period (days 12-17). A comparable agonistic effect of AGs was not observed in systems (2) and (3). Neither HC nor AGs influenced the sialylation pattern of thymocyte membrane bound CD26/DPP IV, which was exclusively of alpha2,6-type, as demonstrated by analytical isoelectric focusing (IEF) and PAGE analysis in combination with the application of neuraminidases, specific lectins and histochemical staining for DPP IV activity in the gels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630094     DOI: 10.1016/j.jsbmb.2003.07.002

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

1.  Enriched environment regulates thymocyte development and alleviates experimental autoimmune encephalomyelitis in mice.

Authors:  Run Xiao; Stephen M Bergin; Wei Huang; Anthony G Mansour; Xianglan Liu; Ryan T Judd; Kyle J Widstrom; Nicholas J Queen; Ryan K Wilkins; Jason J Siu; Seemaab Ali; Michael A Caligiuri; Lei Cao
Journal:  Brain Behav Immun       Date:  2018-10-01       Impact factor: 7.217

2.  Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity.

Authors:  James H Lewis; Paul H Cottu; Martin Lehr; Evan Dick; Todd Shearer; William Rencher; Alice S Bexon; Mario Campone; Andrea Varga; Antoine Italiano
Journal:  Drug Saf       Date:  2020-10       Impact factor: 5.606

3.  Lack of in vitro effect of aglepristone on IFN-γ and IL-4 production by resting and mitogen-activated T cells of luteal bitches.

Authors:  Piotr Jurka; Lidia Szulc-Dąbrowska; Joanna Borkowska; Anna Winnicka
Journal:  BMC Vet Res       Date:  2013-10-26       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.